Skip to main content
An official website of the United States government
Email

NCI Clinical Trials Stewardship Initiative

In 2016, NIH announced the first series of reforms and initiatives to improve quality and efficiency of NIH-funded clinical trials, focused on a variety of key points along the lifespan of a clinical trial. NIH had modified existing policies and created new ones that govern research involving human subjects and their participation in clinical trials. These initiatives reengineer the process by which clinical investigators develop ideas for new trials, how NIH reviews and selects clinical trials for support, oversees research progress, and how results are reported to ensure rigor and efficiency in clinical trials.

Introduction

NCI has taken steps to implement these changes and to achieve more consistency in the conduct and management of clinical trials funded through grants, cooperative agreements, and contracts. Referred to as, “The NCI Clinical Trials Stewardship Initiative,” it continues to build upon NCI’s solid foundation of clinical trials stewardship and is led by a committee of NCI representatives from the various Divisions, Offices, and Centers that support clinical trials. The goal of the initiative is to ensure the following:

  • Quality of clinical trials
  • Safety of research participants
  • Reliability of data
  • Dissemination of results
  • Appropriate stewardship of funds

NIH Policies & Tools for Clinical Trials

NIH launched a multifaceted effort to improve the quality and efficiency of clinical trials by focusing on changes to:

  • The process by which clinical investigators develop ideas for new trials
  • How NIH reviews and selects clinical trials
  • How NIH supports and oversees research progress
  • The process by which results and aggregate data are shared and reported

NIH’s Office of Extramural Research provides additional information on clinical trial requirements for grants and contracts. Specific guidance and tools for various steps in the grant application and contract submission process are listed below.

  • Definition of Human Subjects Research: Establishes the NIH definition of Human Subjects Research and applicable Federal Regulations and NIH Requirements for planning and submitting an application. This includes the NIH definition of an existing dataset or resource.
  • NIH Definition of a Clinical Trial: Establishes the NIH definition of a clinical trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
  • Good Clinical Practice Training for NIH Awardees Involved in NIH-funded Clinical Trials: Establishes the expectation that all NIH-funded investigators and staff who are involved in the conduct, oversight, or management of clinical trials will be trained in Good Clinical Practice (GCP), consistent with principles of the International Conference on Harmonisation (ICH) E6 (R2).

Human Subjects Research Policy Changes

NIH Policy Changes to the Application Submission and Scientific Review Process

  • Notice of Funding Opportunity (NOFO) Announcements for Clinical Trials: All applications involving one or more clinical trials must be submitted through a NOFO specifically designed for clinical trials. The purpose of this policy is to improve the ability for NIH to identify proposed clinical trials, ensure that key pieces of trial-specific information are submitted with applications, and uniformly apply trial-specific review criteria. Applications submitted to the wrong NOFO will be returned without review.
  • Human Subjects and Clinical Trial Information Form: The Human Subjects and Clinical Trial related information form consolidates all human subject and clinical trial information and expands the review criteria information required for studies that meet the NIH definition of a clinical trial. Instructions on how to complete the form, including guidance on content, is described in the NIH Application Guide.
  • NIH and FDA Protocol Template for Phase 2 and 3 IND/IDE Clinical Trials: NIH-FDA has a suggested format for a clinical trial protocol template that NIH investigators can use when writing protocols for phase 2 and 3 clinical trials that require Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications.

New Policy on Dissemination of NIH-Funded Clinical Trial Information

  • Dissemination of NIH-Funded Clinical Trial Information: Establishes the expectation that all investigators conducting clinical trials that are funded in whole or in part by the NIH will ensure that these trials are registered at ClinicalTrials.gov, and that results of these trials are submitted to ClinicalTrials.gov.

NCI Resources for Clinical Trials

NIH Tools/Guidance for Investigators

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “NCI Clinical Trials Stewardship Initiative was originally published by the National Cancer Institute.”

Email